ABSTRACT:
Cancer is one of the major causes of worldwide human mortality. A wide range of cytotoxic drugs are available on the market, and several compounds are in different phases of clinical trials. In recent years, fused pyrimidine derivatives have been considered as a novel class of cancer chemotherapeutic agents that show promising activity against different tumors. The aim of this article is to comprehensively review focused on recent progressions in chemistry and molecular docking by the description of several applications. This strategy enables the hit identification, lead optimization of the designed pyridopyrimidine scaffolds by proceeding molecular docking studies for targeting protein kinases in anticancer activity and which proves a reliable and fast filter in HT virtual screening, thereby providing a pool of ideas for novel lead molecules. In future research has to be carried to fully explore the anticancer efficacy of insilico succeeded molecules through in vitro and in vivo animal models.